

Legal Basis for Disclosure	Medicines for Europe Code of Conduct on Interactions with the Healthcare Community, published February 2015 Updated in January 2016
Reporting Period	2018
Currency of disclosed values	All values are disclosed in Euros
Value identification and Recognition	All values disclosed are based on value transfers actually made within the respective category. Such value transfers have been made to a specific recipient as booked in the respective reporting period.
Data disclosed for	All values are disclosed for Recipients which have been engaged by entities in Europe Recipients having their place of business in European countries
VAT and other taxes	All amounts are disclosed include VAT or similar service taxes, where such apply on the transaction
Disclosure location:	www.lnsudpharma.com

Value category:	The company discloses value transfers in this category as per Option
"Meetings,	2 of the Medicine for Europe Transparency Requirements:
educational support and site visits of HCPs"	Aggregate total amount of support provided to Healthcare Professionals per individual conference or meeting as follows:
	• Sponsorship for attending a third party organized congress (as per section 4.4):
	- name of congress,
	- aggregated amount spent for the congress, including the



	- number of Healthcare Professionals financially supported to attend
	• Site visits (as per section 4.5): aggregated amount spent, including
	the number of Healthcare Professionals financially supported to
	attend.
	Company organized meeting: aggregated amount spent, including
	the number of Healthcare Professionals financially supported to
	attend.
Value	HCP ToV Definition, such as:
Category:Transfer of Values to HCP fees	Educational Services, includes:
for service and consultancy	Speaker fee
	Chairing a meeting
	Training
	Consultancy Services, includes:
	Marketing research
	Advisory Boards
	Training materials
Other Remarks	For value categories related to HCPs, aggregate values have been disclosed where the consent of a multiple number of HCP could not be obtained.
	Fees paid in connection with research & development activities or market research have not been disclosed as per Medicines for
	Europe guidelines